Survey of hydrocodone patients shows schedule changes negatively impact treatment
A survey of pain patients to assess the effects of rescheduling hydrocodone has shown that it negatively impacts doctor-patient relationships and causes higher expenses to the patient.
The survey was conducted by the National Fibromyalgia & Chronic Pain Association, to gauge the effects of rescheduling hydrocodone from Schedule III to Schedule II. It has been the most widely-prescribed medication in the USA, with 130 million annual prescriptions, and is frequently prescribed for pain in combination with other medications.
The new Drug Enforcement Administration regulation which came in October 2014 rescheduled hydrocodone from Schedule III to Schedule II, and limits patients to a smaller maximum supply between doctor visits. It means that patients must now see a prescriber for each handwritten prescription renewal. The goal was to reduce criminal activity and deaths from drug overdoses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze